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Introduction: Healthcare workers (HCWs) are exposed to Mycobacterium tuberculosis (MTB) and therefore are
screened for tuberculosis (TB). Results of TB screenings with the Interferon-γ Release Assay (IGRA) in a French
psychiatric hospital without a TB ward are described.
Methods: At the Sainte-Anne Hospital, a referral centre for psychiatric patients throughout the municipal region of
Paris, IGRA screening is performed during pre-employment and general health examination or after potential
contact to MTB. The QuantiFERON Gold in tube (QFT) is used and data on TB history are assessed in a
standardized manner.
Results: Between August 2008 und August 2013 in total 1.192 HCWs were tested and the QFT was positive in
265 (22.2%). Probability of a positive QFT increased with age. A second QFT was performed in 144 HCWs with a
positive QFT and 53 (36.8%) HCWs had a reversion. With a positive QFT close to the cut-off (e.g. 0.35-0.7 IU/ml)
the odds ratio for a reversion was 4.6 compared to an INF-γ concentration of ≥3.0 IU/ml. Probability of reversion
was not influenced by preventive chemotherapy, which was completed by 28 (19.4%) HCWs with a positive QFT.
No active TB was detected.
Conclusion: Prevalence of positive IGRA is high in French HCWs as is the number of reversions in IGRA.
Reversion rate is particularly high around the cut-off of the IGRA. A borderline zone will therefore reduce the
influence of test variability.
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The risk of contracting tuberculosis (TB) is increased
in healthcare workers’ (HCWs) [1-3]. TB screening for
HCWs is therefore considered a cornerstone for preventing
TB in hospitals [4]. Until now, TB screening was performed
using a tuberculin skin test (TST), which has several weak-
nesses the most important being cross reactivity with BCG
vaccination and booster phenomena due to intradermal
application. The interferon-gamma release assays (IGRA)
are a promising tool to overcome these problems [5-7].* Correspondence: a.nienhaus@uke.de
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tuberculosis they do not show cross reactivity with
BCG vaccination and most non-tuberculosis mycobacteria.
As IGRA are in vitro tests the problem of boosting in serial
testing is circumvented. IGRA correlate better than TST
with exposure to infectious patients [8]. Furthermore, in
low incidence countries IGRA have a higher predictive
value for disease progression [9-11]. Therefore IGRA are
likely to improve both the effectiveness and the efficiency
of HCWs screening [12]. However, interpretation of IGRA
in the serial testing of HCWs remains to be clarified and a
consensus needs to be found as the reversion rate in posi-
tive IGRA seems to be high [7,13-17]. The reversion rate
depends on the quantitative result of the positive first
IGRA. Around the cut-off the reversion rate is particularly
high and the clinical importance of this observation is not
jet well understood. Do they reflect transient infection,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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20- < 25 248 20.8
25- < 30 209 17.5
30- < 40 285 23.9
40- < 50 204 17.1
50- < 60 181 15.2
60+ 50 4.2
Reason for examination
General OH examination 393 33.0
Preemployment screening 769 64.5




TST result known 195 16.4
Second QFT performed 144 12.1
Reversion in IGRA 53 36.8*
*out of 144 with a second QFT.
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of the immune system or just variability by chance [5]?
So far we do not have the answer to this question.
However it is questionable whether HCWs with a posi-
tive but low result in the IGRA should receive preventive
treatment or whether they should be retested before a
decision is made [15,17].
In France the incidence of TB is low (8.9 cases per
100,000 in the year 2007), however the variability of the
incidence rate is high. In the region of Paris the inci-
dence rate is as high as 18.4/100,000. Therefore TB pre-
vention is a public health priority in France [18]. Special
focus is given to nosocomial infections and the screening
of HCWs [19,20]. Since 2007 the French Health Authority
has recommended the use of IGRA for these screenings.
Published data concerning the results of TB-screenings
with IGRA are available from four studies, reporting
prevalence rates of positive IGRA from 12% to 32% while
a TST ≥10 mm was observed in 43% to 70% of HCWs
[21-24]. However data on reversions in IGRA are still
sparse as only one French study covered this subject [24].
At the Sainte-Anne Hospital in Paris TB screening of
HCWs with IGRA was started in 2008 and those HCWs
with a positive IGRA were offered retesting. Therefore
the prevalence of positive IGRA and the reversion rate
of positive IGRA can be described.
Method
The population of this prospective study includes all
workers at the Sainte-Anne Hospital in Paris who partic-
ipated in TB screening between August 2008 and August
2013 due to pre-employment screening, general occupa-
tional health (OH) examination or contact with infectious
TB patients or materials, and on whom an IGRA was
performed. In contact tracings the screening was performed
8 weeks after last contact. The Sainte-Anne Hospital
specializes in psychiatry and it is a referral centre for
psychiatric patients throughout the municipal region of
Paris. The hospital has no TB ward.
Results of the TB screening were assessed in a stan-
dardized database. BCG vaccination for all new-borns
was mandatory in France until 2008 [19]. Therefore it
was assumed that all HCWs were vaccinated, no data on
BCG vaccination was considered in this analysis. The
TST results in history were assessed from the individual
files of the HCWs or by interview. No simultaneous testing
with IGRA and TST was performed. All HCWs with a first
positive IGRA were retested within 3 months. Only if the
second IGRA was positive, too, the respective HCWs was
referred to a specialist for consultation concerning prevent-
ive chemotherapy of latent TB infection (LTBI).
For the IGRA, the QuantiFERON® -TB Gold In-Tube
Assay (QIAGEN, Cellestis) (QFT) was administered in
accordance with the manufacturer’s instructions. As thestudy used anonymous data generated in the scope of
routine OH examinations no approval of an ethics
committee was needed.
Statistical analysis
Chi-square tests were used for categorical data. Adjusted
odds ratios (OR) and 95% confidence intervals (CI) were
calculated for putative predictive variables using conditional
logistic regression. Model building was performed back-
wards using the change criteria for variable selection.
Results
The study population comprises 1.192 HCWs. The study
population is described in Table 1. In total 265 (22.2%)
of the HCWs were positive in IGRA (Figure 1). No dif-
ference was observed between male and female HCWs
concerning IGRA results (Table 2). Prevalence of posi-
tive IGRA increased with age, if the very young age group
(<20 years) is disregarded. No difference was observed
regarding the reason for the test, general screening or
pre-employment screening. A second IGRA was performed
in 144 HCWs with a positive IGRA (55.5%) and a negative
second IGRA was observed in 53 HCWs (36.8%). The re-
sults of a TST in history were documented for 195 HCWs
(16.4%). The TST was below 10 mm in 32.8% and at least











Figure 1 Flow chart of the study population.
1,192 HCW with QFT
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positive in HCWs with a positive TST (85.5 versus 73.4%,
p = 0.04) than in those with a negative TST in history.
Reversions were more likely in those with a negative
TST in history (60.7 versus 31.9%, p = 0.008). Further-
more reversions were less likely when the IGRA was
taken because of a pre-employment screening and
more likely when the second IGRA was performed
within three months after the first IGRA (OR 2.3; 95%
CI 1.2-6.8) (Table 3). If the concentration of the INF-γTable 2 Risk factors for a positive QFT
QFT positive
N % OR 95% CI
Female 152 19.3 1 –
Male 83 22.3 1.2 0.9 – 1.6
Age in years
<20 4 26.7 2.2 0.7 – 7.4
20- < 25 34 14.0 1 –
25- < 30 33 16.1 1.2 0.7 – 7.4
30- < 40 55 19.7 1.5 0.7 – 2.0
40- < 50 46 22.8 1.8 1.1 – 3.0
50- < 60 48 28.2 2.4 1.5 – 4.0
60+ 15 31.3 2.8 1.4 – 5.7
Reason for examination
General OH exam 83 21.1 1 –
Pre-employment 152 19.8 1.2 0.9 – 1.7
Contact tracing* 30 100.0 –
*30 HCWs, who were examined because of a contact tracing, where excluded
from the model as all 30 HCWs had a positive QFT.was between 0.35 and <0.7 IU/ml the probability of a
reversion was increased (OR 4.6, 95% CI 1.6-13.4). If
the IFN-γ concentration was at least 3.0 IU/ml in the
first QFT, probability of a reversion was still 20%. No


















p = 0.008 
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Figure 2 Flow chart of HCWs with a TST in history.
Table 3 Risk factors for reversion
QFT reversion
Reason for examination N % OR 95% CI
General OH exam 26 48.1 1 –
Pre-employment 20 26.7 0.3 0.1 – 0.9
Contact tracing 7 46.7 1.3 0.4 – 4.6
Time between the QFT
<3 months 28 45.9 2.3 1.2 – 6.8
3+ months 25 30.1 1 –
Concentration of first QFT
0.35- < 0.7 IU/ml 20 55.6 4.6 1.6 – 13.4
0.7- < 1.0 IU/ml 9 30.6 2.2 0.7 – 7.5
1.0- < 3.0 IU/ml 15 39.5 2.4 0.8 – 7.1
3.0+ IU/ml 9 20.0 1 –
TST in history
10 +mm 23 31.9 1
<10mm 17 60.7 4.4 1.6 – 12.2
Unknown, not performed 13 29.5 1.3 0.5 – 3.2
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To our knowledge this study is the first to describe a
positive association between age and positive IGRA re-
sults in French HCWs. Furthermore we observed a high
reversion rate of IGRA in HCWs, which was highest
when the INF-γ concentration of the first IGRA was
between > =0.35 and < 0.7 IU and when the second IGRA
was repeated within 3 months after the first IGRA. No ac-
tive TB was diagnosed within the scope of the study and
the prevalence of positive IGRA was lower than the preva-
lence of positive TST in history.
As most French HCWs are BCG vaccinated the discrep-
ancy between TST and IGRA results are well explained. In
so far our study corroborates the observations of other
studies [23-25]. A high reversion rate of positive IGRA
was reported by other studies before [26-33]. As no active
TB cases were observed in our study, information for the
clinical interpretation of a reversion in IGRA cannot be
derived from our data. As the TB risk in our collective
seems to be low, it might be safe to conclude that HCWs
with a reversion in IGRA will not profit from preventive
chemotherapy. In line with this it was proposed that QFTs
with an INF-γ concentration between 0.35 and 1.11 IU/ml
should be repeated before any other action (X-ray, referral
to expert or chemoprevention) is taken in low risk HCWs
[15]. Surprisingly, the reversion rate was higher when the
IGRA was repeated within three months of the first IGRA.
The delay in repeating a first positive IGRA was based on
organizational hinders, which should not have influenced
the IGRA results.As only HCWs with positive IGRA results were retested,
no information on conversion rates in French HCWs can
be derived from our study. In a German low risk group no
conversion was observed when a borderline zone for the
QFT of 0.2 to 0.7 IU/ml was applied [34,35]. However,
recently several reports were published about higher
conversion rates in IGRA than in TST [36-39]. This
might indicate that some of the conversions of the
IGRA are explained by chance or measurement vari-
ability. As IGRA conversion rates are higher when the
INF-γ of the first IGRA is close to the cut-off, it seems
reasonable to introduce a borderline zone for IGRA in-
terpretation in serial testing or to define a minimum
increase in INF-γ concentration that need to be exceeded
for a conversion. In addition it seems reasonable to repeat
all first time IGRAs which are positive and to perform
X-ray for the exclusion of active TB in the absence of
clinical symptoms or preventive chemotherapy only in
those HCWs with a confirmed positive IGRA.
Conclusion
Prevalence of positive IGRA is high in French HCWs as
is the number of reversions in IGRA. Reversion rate is
particularly high around the cut-off of the IGRA. Before
chemoprevention is administered the IGRA should be
repeated as HCWs with a reversion in IGRA will most
likely not profit from preventive treatment. In HCWs
with a reversion in IGRA and no clinical symptoms it
seems save not to perform an X-ray. More research is
needed in order to better understand the variability of
IGRA results. Ultimately a more stable IGRA seems to
be desirable.
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